Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 986 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1: Severely Renal Impaired Participants | EXPERIMENTAL | Participants with severely impaired renal function (estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m\^2) receive a single oral dose of 200 mg AMG 986. |
| Group 2: Healthy Participants | ACTIVE_COMPARATOR | Participants with normal renal function (eGFR \>= 90 mL/min/1.73 m\^2 or above) receive a single oral dose of 200 mg AMG 986. |
| Name | Type | Description |
|---|---|---|
| AMG 986 | DRUG | tablets for oral administration |
Inclusion Criteria: * Male or female subjects, who are \> or = 18 and \< or = 65 years of age at the time of screening * Subject has provided informed consent prior to initiation of any study-specific activities/procedures * Women must be of non-reproductive potential (ie, postmenopausal, history o...
Top 20 of 31 competitors
AMG 986 is an investigational small molecule being developed by Amgen Inc. for the treatment of heart failure. It is currently in Phase 1 clinical development, meaning it is still being studied and has not been approved for use.
AMG 986 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 1 clinical trials for heart failure.
AMG 986 is in Phase 1 clinical development. It is an investigational drug for heart failure and has not been approved by regulatory authorities. The drug is still being studied for safety, tolerability, and pharmacokinetics.
AMG 986 has one completed Phase 1 clinical trial, identified as NCT03318809. This study evaluated the safety, tolerability, and pharmacokinetics of AMG 986 administered orally to healthy volunteers and participants with severely impaired renal function in the United States.
AMG 986 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for heart failure. The drug is still being studied and has not been approved for any use.